ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

Why MEK Inhibitor SHR 7390 is on this study

  • The record lists it as a treatment, written “SHR7390”.
  • Claude Opus 5.5 judged it tested: part of what the study tests. Nov 3, 2026, 1:53 PM UTC
  • The role rule says the same.
  • So MEK Inhibitor SHR 7390's page lists this study under “Testing it”.
16 links0 made here, not in the record29 judgments2 judges (the rules as one: Rule based)1 record change seen
Claude Opus 5.5Rule basedRecord updated on ClinicalTrials.gov
Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT04355858Molecularly TargetedUmbrella Study in LuminalAdvanced Breast CancerFudan UniversityPhase 2 · unknownRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Nov 8 · ClinicalTrials.gov record · MeSH filing re-derivedMeSH filing re-derivedCONDITIONSBreast NeoplasmsThe registry's MeSH filing›As of now · Rule based · Main conditionMain conditionNeoplasm MetastasisThe registry's MeSH filing›No judgment recorded. Shown as the registry files it.DRUGSMEK Inhibitor SHR 7390Entry “SHR7390”, read by our name rule›Nov 3 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedFamitinibIntervention entry›Nov 3 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedFluzoparibEntry “SHR3162”, read by our name rule›Nov 3 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedPyrotinibIntervention entry›Nov 3 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedCapecitabineIntervention entry›Nov 3 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundCamrelizumabEntry “SHR1210”, read by our name rule›Nov 3 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedEverolimusIntervention entry›Nov 3 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedAlbumin-Bound PaclitaxelEntry “Nab paclitaxel”, read by our n…›Nov 3 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedZeprumetostatEntry “SHR2554”, read by our name rule›Nov 3 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedRezvilutamideEntry “SHR3680”, read by our name rule›Nov 3 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedDalpiciclibEntry “SHR6390”, read by our name rule›Nov 3 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedSHR-1701Entry “SHR1701”, read by our name rule›Nov 3 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedFulvestrantEntry “SERD”, read by our name rule›Nov 3 · Claude Opus 5.5 · Background · partnerNov 18 · Rule based · BackgroundBackground · partnerAromatase inhibitorsEntry “AI”, read by our name rule›Nov 3 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackground

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

All judgments on this study

WhenLinkJudgeDecisionState
Nov 3MEK Inhibitor SHR 7390Claude Opus 5.5TestedCurrent
Nov 3FamitinibClaude Opus 5.5TestedCurrent
Nov 3FluzoparibClaude Opus 5.5TestedCurrent
Nov 3PyrotinibClaude Opus 5.5TestedCurrent
Nov 3CapecitabineClaude Opus 5.5BackgroundCurrent
Nov 3CamrelizumabClaude Opus 5.5TestedCurrent
Nov 3EverolimusClaude Opus 5.5TestedCurrent
Nov 3Albumin-Bound PaclitaxelClaude Opus 5.5TestedCurrent
Nov 3ZeprumetostatClaude Opus 5.5TestedCurrent
Nov 3RezvilutamideClaude Opus 5.5TestedCurrent
Nov 3DalpiciclibClaude Opus 5.5TestedCurrent
Nov 3SHR-1701Claude Opus 5.5TestedCurrent
Nov 3FulvestrantClaude Opus 5.5Background · partnerCurrent
Nov 3Aromatase inhibitorsClaude Opus 5.5BackgroundCurrent
Nov 8The record itselfClinicalTrials.gov recordMeSH filing re-derivedRecord change
Nov 18MEK Inhibitor SHR 7390Rule based · role ruleTestedAgrees
Nov 18FamitinibRule based · role ruleTestedAgrees
Nov 18FluzoparibRule based · role ruleTestedAgrees
Nov 18PyrotinibRule based · role ruleTestedAgrees
Nov 18CapecitabineRule based · role ruleBackgroundAgrees
Nov 18CamrelizumabRule based · role ruleTestedAgrees
Nov 18EverolimusRule based · role ruleTestedAgrees
Nov 18Albumin-Bound PaclitaxelRule based · role ruleTestedAgrees
Nov 18ZeprumetostatRule based · role ruleTestedAgrees
Nov 18RezvilutamideRule based · role ruleTestedAgrees
Nov 18DalpiciclibRule based · role ruleTestedAgrees
Nov 18SHR-1701Rule based · role ruleTestedAgrees
Nov 18FulvestrantRule based · role ruleBackgroundAgrees
Nov 18Aromatase inhibitorsRule based · role ruleBackgroundAgrees
As of nowBreast NeoplasmsRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.